IntraBio

IntraBio Inc. is a biopharmaceutical company with a late-stage drug pipeline, including new therapies for common and rare neurodegenerative diseases. IntraBio's platform technology stems from decades of research and investment at world-class universities and institutions. Its clinical programs leverage the scientific founders' expertise in lysosomal function and intracellular calcium signaling from Oxford University and the University of Munich. IntraBio's management team and advisors have a proven track record of successful drug development in both the United States and Europe. The team translates innovative scientific research in lysosomal biology, autophagy, and neurology into novel drugs for a wide range of genetic and neurodegenerative diseases, significantly improving patients' lives.